Dengue vaccination in Brazil

Resumen

Since the establishment of vaccines as a preventive method for diseases, especially epidemic ones, science has always sought in them the solution to major public health problems such as Dengue, an endemic disease in several tropical countries with large populations. Brazil is one of the countries that seasonally suffers from an increase in cases every year. Many vaccine development techniques have emerged over the past few decades and have provided possibilities to build effective vaccines against diseases that always presented major prevention challenges. Several vaccines against dengue currently exist and among them, Dengvaxia®, from the company Sanofi Pasteur, was the first to prove effective without causing worrying side effects. Another vaccine that deserves to be highlighted is the Qdenga vaccine, the first approved in Brazil for a wider audience (from four to 60 years of age). Thus, the methodology applied for the present study was a bibliographic survey using available internet research tools, such as the bibliographic database of the Virtual Health Library (VHL/BIREME), Google Scholar, the epidemiological bulletins of the Ministry of Health and searches on the website of the National Health Surveillance Agency and the company Sanofi Pasteur. The data presented were on the Dengvaxia vaccine, the Qdenga vaccine and the promising vaccine produced by the Butatan Institute. Regarding the efficacy of vaccines, Qdenga is mainly supported by the results of a large-scale study and Dengvaxia through vaccination campaigns can be considered important in regions with a higher incidence of dengue. The objective of this paper is to report the vaccination against dengue in Brazil and to emphasize the efficacy of the vaccines currently applied.

DOI:https://doi.org/10.56238/sevenIVmulti2023-124